



Alamar Biosciences Announces \$128M Series C to Accelerate Commercialization of its Proteomics Platform

Client News

February 26, 2024

Gunderson Dettmer represented life sciences client Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, in its \$128 million Series C financing led by Sands Capital.

In the [announcement of the transaction](#), Alamar Biosciences CEO and Chairman Dr. Yuling Luo said, “We are extremely grateful for the strong support we have received from this premium group of investors in this significantly oversubscribed round. It is a testament to our game changing technology, solid IP, and strong early market adoption. Our proprietary NULISA™ technology has demonstrated superior performance and a unique combination of capabilities that will enable our customers to accelerate biomarker discovery and the development of non-invasive tests for diseases with high unmet need. With this funding, we are now well positioned to power precision proteomics through accelerated commercialization.”

Earlier this year, Alamar announced the commercial launch of the ARGO™ HT System and the NULISAseq™ Inflammation Panel 250 for deep profiling of immune response. Alamar’s NULISA technology utilizes a novel sequential capture and release method to purify the immune complex, improving signal-to-noise by more than 10,000-fold. It also provides corresponding increases in sensitivity and dynamic range in comparison with traditional immunoassay approaches. The ARGO HT System provides an automated method for running NULISA assays with less than 30 minutes of total hands-on time. With qPCR and NGS readouts, the NULISA platform enables both focused analysis of validated biomarkers and highly multiplexed

profiling of hundreds to ultimately thousands of proteins. The new capital will be used to grow the commercial and customer support teams, drive market adoption and expand the product menu.

The Gunderson Dettmer deal team was led by Ivan Gaviria and included Nate Gray, Chase Beckstead, Maddy Kerr Hyde, Mark Foster, Michael Richman, Gina Marek, Julie Mahoney, Margaret Lynch and Greg Kinzelman.

Companies

Alamar Biosciences

Sands Capital

Related People

Ivan Gaviria

PARTNER

P +1 650 321 2400

Nathaniel F. Gray

ASSOCIATE

P +1 415 801 4922

Chase N. Beckstead

ASSOCIATE

P +1 650 463 5379

Mark M. Foster

PARTNER

P +1 650 463 5343

Michael N. Richman

PARTNER

P +1 650 463 5287

Gina M. Marek

PARTNER

P +1 650 463 5242

Julie C. Mahoney
ASSOCIATE
P +1 650 463 5220

Gregory L. Kinzelman
PARTNER
P +1 646 797 5528

Related Services

Late-Stage Company
Life Sciences Licensing & Strategic Partnering
Private & Public Companies

Featured Insights

FIRM NEWS

Gunderson Dettmer Commemorates 2025 Asian American and Pacific Islander Heritage (AAPI) Month

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act

INSIGHTS

Client Insight: Prepare for BE-10 Benchmark Survey of US Direct Investment Abroad

INSIGHTS

Tech Brew Interviews Aaron Rubin in “Where the legal battle stands around copyright and AI training”

CLIENT NEWS

Latin America Fintech Belvo Announces \$15M Funding